Anti-phospholipid syndrome: clinical spectrum and therapeutical/prophylactic strategies in the pediatric population

Donato Rigante, Giulia Bersani, S. Gaspari, A. Stabile

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

Anti-phospholipid syndrome (APS) is a potentially life-threatening autoimmune condition characterized by the presence of anti-phospholipid antibodies (aPL) giving rise to increased hypercoagulability, which induces venous or arterial thrombotic events at whatever age and recurrent fetal loss in the fertile age. Antigens that are targeted by aPL include cardiolipin and beta2-glycoprotein I. Primary APS is defined in the absence of an underlying disease, while secondary APS is observed in the context of another established pathological condition. APS has a wide variety of clinical signs and serological characteristics. This paper describes the current approaches towards diagnosis, therapeutic modalities and secondary prevention applied to children.
Lingua originaleEnglish
pagine (da-a)47-53
Numero di pagine7
RivistaEuropean Review for Medical and Pharmacological Sciences
Volume2008
Stato di pubblicazionePubblicato - 2008

Keywords

  • Antiphospholipid syndrome

Fingerprint

Entra nei temi di ricerca di 'Anti-phospholipid syndrome: clinical spectrum and therapeutical/prophylactic strategies in the pediatric population'. Insieme formano una fingerprint unica.

Cita questo